• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . 400 AU/mL IgG protective threshold against SARS-CoV-2 XBB reinfection in Chinese inactivated vaccine recipients: implications for b

tetano

Editor, Senior Moderator
Front Immunol


. 2026 Feb 19:17:1768679.
doi: 10.3389/fimmu.2026.1768679. eCollection 2026.
400 AU/mL IgG protective threshold against SARS-CoV-2 XBB reinfection in Chinese inactivated vaccine recipients: implications for booster vaccination

Zhiying Yin[SUP] #[/SUP][SUP] 1 [/SUP], Mengcheng Yin[SUP] #[/SUP][SUP] 2 [/SUP], Fei Zhao[SUP] #[/SUP][SUP] 3 [/SUP], Canya Fu[SUP] 3 [/SUP], Wenjie Xu[SUP] 1 [/SUP], Quanjun Fang[SUP] 1 [/SUP], Xiaoying Gong[SUP] 1 [/SUP], Shuangqing Wang[SUP] 1 [/SUP], Canjie Zheng[SUP] 1 [/SUP]


Affiliations
Abstract

Background: Data on antibody dynamics and protective threshold generated by infection with Omicron subvariants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly among populations that have primarily (>90%) received inactivated coronavirus disease 2019 (COVID-19) vaccines, remain limited. Using data from two large-scale paired serosurveys, we analyzed real-world changes in SARS-CoV-2 antibody levels associated with specific hybrid immunity.
Methods: The history of COVID-19 vaccination and SARS-CoV-2 infection were recorded for each participant. Serum samples collected at three-month intervals were analyzed for antibody levels against nucleocapsid (N) and spike (S) proteins using chemiluminescent microparticle immunoassay (CMIA). Linear mixed-effects model (LMM) and restricted cubic spline analysis were applied to assess antibody dynamics and determine protection thresholds, respectively.
Results: A total of 4,065 participants were recruited in February and May 2023, with 2,894 completing both sampling rounds. Over three months, median IgG antibody levels declined by 28% (from 396.39 to 285.80 AU/mL). Prior infection and vaccination were significantly associated with higher antibody levels, while increasing age correlated with an annual decay of 0.38 AU/mL (most prominent in adults ≥60 years, 32.7% of whom fell below the protective threshold by follow-up). The IgG threshold for protection against XBB reinfection was 400 AU/mL, and each additional vaccination reduced reinfection risk by 13-15%.
Conclusion: The 400 AU/mL IgG threshold provides a actionable quantitative guideline for prioritizing booster doses in Chinese adults aged ≥60 years (the fastest antibody decay subgroup) and high-risk groups. Routine antibody testing combined with this threshold could optimize targeted COVID-19 vaccination strategies in inactivated vaccine-predominant populations.

Keywords: SARS-CoV-2; antibody dynamics; hybrid immunity; inactivated vaccine; protective threshold.

 
Back
Top Bottom